<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412801</url>
  </required_header>
  <id_info>
    <org_study_id>V98_05</org_study_id>
    <nct_id>NCT01412801</nct_id>
  </id_info>
  <brief_title>Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings</brief_title>
  <official_title>A Phase II Open-Label, Multi-Center Study of a Group B Streptococcus Vaccine in HIV Positive and HIV Negative Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The study compared the magnitude of the antibody response and safety of a GBS Trivalent
      Vaccine in HIV positive and HIV negative pregnant women and their offspring. In addition the
      study investigated the maternal to fetal transfer of antibodies induced by the
      investigational vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Antibodies in Maternal Subjects and Infants at Delivery/Birth</measure>
    <time_frame>Day of delivery/birth</time_frame>
    <description>GMCs of Group B Streptococcus (GBS)-specific Abs against serotypes Ia, Ib and III in mothers and in infants at delivery/birth are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Transfer Ratio Between Infant Antibody Level (μg/mL) and Maternal Antibody Level (μg/mL), for GBS Serotypes Ia, Ib and III at Delivery/Birth.</measure>
    <time_frame>Day of delivery/birth</time_frame>
    <description>The Geometric mean transfer ratio of GBS-specific Ab against serotypes Ia, Ib and III at delivery is calculated as the geometric mean of the pairwise ratios between the antibody concentrations from infant at birth and to maternal serum concentration at delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaccine Induced Maternal Serotype Specific GBS Antibody Levels for GBS Serotypes Ia, Ib and III at Day 1, 15, 31 and at Delivery</measure>
    <time_frame>Day 1, 15, 31 and at Delivery</time_frame>
    <description>Immunogenicity was measured as Geometric Mean Concentration of Antibody levels for GBS Serotypes Ia, Ib and III after receiving one dose of GBS Trivalent Vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Maternal Subjects With The Enzyme-linked Immunosorbent Assay (ELISA) Antibody Levels for GBS Serotypes Ia, Ib and III Above a Specific Threshold at Delivery</measure>
    <time_frame>Day of Delivery</time_frame>
    <description>Immunogenicity was measured in terms of the percentages of maternal subjects with ELISA Antibody Levels for GBS Serotypes Ia, Ib and III Above a Specific Threshold after receiving one dose of GBS Trivalent Vaccine.Threshold values of 0.1, 0.2, 0.5, 1, 2, 3, 5, and 8 μg/mL were used for serum concentrations for maternal subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Solicited Local Adverse Events (AEs)</measure>
    <time_frame>From 6 Hours to Day 7 After Each Vaccination, for up to 24 weeks</time_frame>
    <description>Safety was assessed in terms of the number of subjects with solicited local AEs after receiving one dose of the GBS Trivalent Vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Solicited Systemic AEs</measure>
    <time_frame>From 6 Hours to Day 7 After Each Vaccination, for up to 24 weeks</time_frame>
    <description>Safety was assessed in terms of the number of subjects with solicited systemic AEs after receiving one dose of the GBS Trivalent Vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Who Experienced Unsolicited Adverse Events</measure>
    <time_frame>Day 1 to Study Termination, for up to 24 weeks</time_frame>
    <description>Safety was assessed in terms of the number of subjects who experienced Unsolicited Adverse Events after receiving one dose of the GBS Trivalent Vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Infants Who Experienced Unsolicited Adverse Events</measure>
    <time_frame>Birth to Study Termination, for up to 24 weeks</time_frame>
    <description>Safety in Infants was assessed in terms of the number of subjects who experienced Unsolicited Adverse Events since birth to study termination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Streptococcal Infections</condition>
  <condition>Gram-Positive Bacterial Infections</condition>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>HIVneg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of Group B streptococcus vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIVposCD4HIGH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/µL received one dose of Group B streptococcus vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIVposCD4LOW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL received one dose of Group B streptococcus vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B streptococcus vaccine</intervention_name>
    <description>Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.</description>
    <arm_group_label>HIVneg</arm_group_label>
    <arm_group_label>HIVposCD4HIGH</arm_group_label>
    <arm_group_label>HIVposCD4LOW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women 18-40 years of age between 24-35 weeks gestation

          -  Women who were HIVneg or HIVpos with WHO stage I or II disease and with CD4+ counts &gt;
             50 cells/µL

        Exclusion Criteria:

          -  Women who had CD4+ count ≤ 50 cells/µL

          -  Women who were HIVpos with WHO stage III or IV disease, history of severe allergic
             reactions after previous vaccinations
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Limbe Health Center</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Bertsham</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <results_first_submitted>June 20, 2014</results_first_submitted>
  <results_first_submitted_qc>September 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2014</results_first_posted>
  <last_update_submitted>September 5, 2014</last_update_submitted>
  <last_update_submitted_qc>September 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Group B streptococcus</keyword>
  <keyword>GBS</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Prevention of group B streptococcus infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Streptococcal Infections</mesh_term>
    <mesh_term>Gram-Positive Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at Malawi and South Africa</recruitment_details>
      <pre_assignment_details>All the enrolled subjects are included in the trial. Also,only the mothers who received the glycoconjugates were considered enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HIVposCD4LOW_Maternal</title>
          <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
        </group>
        <group group_id="P2">
          <title>HIVposCD4HIGH_Maternal</title>
          <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
        </group>
        <group group_id="P3">
          <title>HIVneg_Maternal</title>
          <description>HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
        </group>
        <group group_id="P4">
          <title>HIVposCD4LOW(Infants)</title>
          <description>Infants born to HIV-antibody positive maternal subjects with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL .</description>
        </group>
        <group group_id="P5">
          <title>HIVposCD4HIGH(Infants)</title>
          <description>Infants born to HIV-antibody positive maternal subjects with CD4+ count &gt;350 cells/µL</description>
        </group>
        <group group_id="P6">
          <title>HIVneg(Infants)</title>
          <description>Infants born to HIV-antibody negative maternal subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="91"/>
                <participants group_id="P5" count="88"/>
                <participants group_id="P6" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="87"/>
                <participants group_id="P5" count="85"/>
                <participants group_id="P6" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocated to another area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIVposCD4LOW_Maternal</title>
          <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
        </group>
        <group group_id="B2">
          <title>HIVposCD4HIGH_Maternal</title>
          <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
        </group>
        <group group_id="B3">
          <title>HIVneg_Maternal</title>
          <description>HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
        </group>
        <group group_id="B4">
          <title>HIVposCD4LOW (Infants)</title>
          <description>Infants born to HIV-antibody positive maternal subjects with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL</description>
        </group>
        <group group_id="B5">
          <title>HIVposCD4HIGH (Infants)</title>
          <description>Infants born to HIV-antibody positive maternal subjects with CD4+ count &gt;350 cells/µL</description>
        </group>
        <group group_id="B6">
          <title>HIVneg (Infants)</title>
          <description>Infants born to HIV-antibody negative maternal subjects</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="90"/>
            <count group_id="B4" value="91"/>
            <count group_id="B5" value="88"/>
            <count group_id="B6" value="87"/>
            <count group_id="B7" value="536"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Maternal Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="4.8"/>
                    <measurement group_id="B2" value="28.1" spread="5.2"/>
                    <measurement group_id="B3" value="24.7" spread="4.4"/>
                    <measurement group_id="B4" value="NA">&quot;Mothers' ages only provided Here&quot;</measurement>
                    <measurement group_id="B5" value="NA">&quot;Mothers' ages only provided Here&quot;</measurement>
                    <measurement group_id="B6" value="NA">&quot;Mothers' ages only provided Here&quot;</measurement>
                    <measurement group_id="B7" value="27.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Infants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">&quot;Infants' ages only provided here&quot;</measurement>
                    <measurement group_id="B2" value="NA">&quot;Infants' ages only provided here&quot;</measurement>
                    <measurement group_id="B3" value="NA">&quot;Infants' ages only provided here&quot;</measurement>
                    <measurement group_id="B4" value="4.1" spread="1.6"/>
                    <measurement group_id="B5" value="6.7" spread="2.5"/>
                    <measurement group_id="B6" value="1.3" spread="1.1"/>
                    <measurement group_id="B7" value="1.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="41"/>
                    <measurement group_id="B7" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations (GMCs) of Antibodies in Maternal Subjects and Infants at Delivery/Birth</title>
        <description>GMCs of Group B Streptococcus (GBS)-specific Abs against serotypes Ia, Ib and III in mothers and in infants at delivery/birth are presented.</description>
        <time_frame>Day of delivery/birth</time_frame>
        <population>Full Analysis Set (FAS)-Maternal and Infant Subjects: Maternal subjects provided at least one evaluable serum sample result at delivery; infant subjects provided at least one evaluable sample result at birth (from cord blood, or peripheral blood within 72 hours when cord blood was unavailable).</population>
        <group_list>
          <group group_id="O1">
            <title>HIVposCD4LOW_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O2">
            <title>HIVposCD4HIGH_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O3">
            <title>HIVneg_Maternal</title>
            <description>HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O4">
            <title>HIVposCD4LOW(Infants)</title>
            <description>Infants born to HIV-antibody positive maternal subjects with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL .</description>
          </group>
          <group group_id="O5">
            <title>HIVposCD4HIGH(Infants)</title>
            <description>Infants born to HIV-antibody positive maternal subjects with CD4+ count &gt;350 cells/µL</description>
          </group>
          <group group_id="O6">
            <title>HIVneg(Infants)</title>
            <description>Infants born to HIV-antibody negative maternal subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) of Antibodies in Maternal Subjects and Infants at Delivery/Birth</title>
          <description>GMCs of Group B Streptococcus (GBS)-specific Abs against serotypes Ia, Ib and III in mothers and in infants at delivery/birth are presented.</description>
          <population>Full Analysis Set (FAS)-Maternal and Infant Subjects: Maternal subjects provided at least one evaluable serum sample result at delivery; infant subjects provided at least one evaluable sample result at birth (from cord blood, or peripheral blood within 72 hours when cord blood was unavailable).</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="81"/>
                <count group_id="O6" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GBS serotypes Ia (83, 81, 83, 79, 81, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" lower_limit="1.44" upper_limit="2.98"/>
                    <measurement group_id="O2" value="2.31" lower_limit="1.6" upper_limit="3.34"/>
                    <measurement group_id="O3" value="3.98" lower_limit="2.75" upper_limit="5.74"/>
                    <measurement group_id="O4" value="1.01" lower_limit="0.66" upper_limit="1.56"/>
                    <measurement group_id="O5" value="1.22" lower_limit="0.8" upper_limit="1.87"/>
                    <measurement group_id="O6" value="3.91" lower_limit="2.56" upper_limit="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GBS serotypes Ib(74, 80, 82, 44, 56, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" lower_limit="1.22" upper_limit="2.77"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.64" upper_limit="3.52"/>
                    <measurement group_id="O3" value="4.08" lower_limit="2.85" upper_limit="5.83"/>
                    <measurement group_id="O4" value="1.31" lower_limit="0.78" upper_limit="2.19"/>
                    <measurement group_id="O5" value="1.62" lower_limit="1.03" upper_limit="2.56"/>
                    <measurement group_id="O6" value="2.67" lower_limit="1.7" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GBS serotypes III (83, 72, 82, 54, 51, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.71" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.69" upper_limit="1.53"/>
                    <measurement group_id="O3" value="3.61" lower_limit="2.51" upper_limit="5.18"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.36" upper_limit="0.99"/>
                    <measurement group_id="O5" value="0.52" lower_limit="0.31" upper_limit="0.88"/>
                    <measurement group_id="O6" value="3.88" lower_limit="2.47" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Induced Maternal Serotype Specific GBS Antibody Levels for GBS Serotypes Ia, Ib and III at Day 1, 15, 31 and at Delivery</title>
        <description>Immunogenicity was measured as Geometric Mean Concentration of Antibody levels for GBS Serotypes Ia, Ib and III after receiving one dose of GBS Trivalent Vaccine.</description>
        <time_frame>Day 1, 15, 31 and at Delivery</time_frame>
        <population>FAS (Maternal Subjects in the Exposed Population) who -Secondary objective serum GMC: provided at least one evaluable sample result at day 1 (prior to vaccination), day 15, day 31, or at delivery;- Secondary objective kinetics: provided at least one evaluable serum sample at day 1 (prior to vaccination), day 15, day 31, and at delivery.</population>
        <group_list>
          <group group_id="O1">
            <title>HIVposCD4LOW_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O2">
            <title>HIVposCD4HIGH_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O3">
            <title>HIVneg_Maternal</title>
            <description>HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Induced Maternal Serotype Specific GBS Antibody Levels for GBS Serotypes Ia, Ib and III at Day 1, 15, 31 and at Delivery</title>
          <description>Immunogenicity was measured as Geometric Mean Concentration of Antibody levels for GBS Serotypes Ia, Ib and III after receiving one dose of GBS Trivalent Vaccine.</description>
          <population>FAS (Maternal Subjects in the Exposed Population) who -Secondary objective serum GMC: provided at least one evaluable sample result at day 1 (prior to vaccination), day 15, day 31, or at delivery;- Secondary objective kinetics: provided at least one evaluable serum sample at day 1 (prior to vaccination), day 15, day 31, and at delivery.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.19" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.2" upper_limit="0.32"/>
                    <measurement group_id="O3" value="0.38" lower_limit="0.3" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" lower_limit="1.64" upper_limit="4.17"/>
                    <measurement group_id="O2" value="2.95" lower_limit="1.86" upper_limit="4.69"/>
                    <measurement group_id="O3" value="5.61" lower_limit="3.56" upper_limit="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia Day 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" lower_limit="1.75" upper_limit="4.1"/>
                    <measurement group_id="O2" value="3.26" lower_limit="2.14" upper_limit="4.98"/>
                    <measurement group_id="O3" value="6.63" lower_limit="4.37" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia At delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" lower_limit="1.5" upper_limit="3.29"/>
                    <measurement group_id="O2" value="2.69" lower_limit="1.82" upper_limit="3.98"/>
                    <measurement group_id="O3" value="4.49" lower_limit="3.06" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" lower_limit="0.38" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.27" upper_limit="0.48"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.31" upper_limit="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" lower_limit="1.73" upper_limit="4.95"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.17" upper_limit="5.65"/>
                    <measurement group_id="O3" value="6.07" lower_limit="3.98" upper_limit="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib Day 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" lower_limit="1.62" upper_limit="4.24"/>
                    <measurement group_id="O2" value="3.68" lower_limit="2.38" upper_limit="5.7"/>
                    <measurement group_id="O3" value="5.35" lower_limit="3.63" upper_limit="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib At delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="1.36" upper_limit="3.31"/>
                    <measurement group_id="O2" value="3.04" lower_limit="2.03" upper_limit="4.56"/>
                    <measurement group_id="O3" value="3.84" lower_limit="2.69" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.086" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.099" lower_limit="0.072" upper_limit="0.14"/>
                    <measurement group_id="O3" value="0.14" lower_limit="0.1" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="0.79" upper_limit="1.95"/>
                    <measurement group_id="O2" value="1.52" lower_limit="0.97" upper_limit="2.36"/>
                    <measurement group_id="O3" value="5.9" lower_limit="3.99" upper_limit="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III Day 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="0.97" upper_limit="2.35"/>
                    <measurement group_id="O2" value="1.31" lower_limit="0.85" upper_limit="2.02"/>
                    <measurement group_id="O3" value="5.35" lower_limit="3.66" upper_limit="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III At delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.81" upper_limit="1.94"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.7" upper_limit="1.65"/>
                    <measurement group_id="O3" value="3.8" lower_limit="2.61" upper_limit="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Maternal Subjects With The Enzyme-linked Immunosorbent Assay (ELISA) Antibody Levels for GBS Serotypes Ia, Ib and III Above a Specific Threshold at Delivery</title>
        <description>Immunogenicity was measured in terms of the percentages of maternal subjects with ELISA Antibody Levels for GBS Serotypes Ia, Ib and III Above a Specific Threshold after receiving one dose of GBS Trivalent Vaccine.Threshold values of 0.1, 0.2, 0.5, 1, 2, 3, 5, and 8 μg/mL were used for serum concentrations for maternal subjects.</description>
        <time_frame>Day of Delivery</time_frame>
        <population>FAS (Maternal Subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>HIVposCD4LOW_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O2">
            <title>HIVposCD4HIGH_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O3">
            <title>HIVneg_Maternal</title>
            <description>HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Maternal Subjects With The Enzyme-linked Immunosorbent Assay (ELISA) Antibody Levels for GBS Serotypes Ia, Ib and III Above a Specific Threshold at Delivery</title>
          <description>Immunogenicity was measured in terms of the percentages of maternal subjects with ELISA Antibody Levels for GBS Serotypes Ia, Ib and III Above a Specific Threshold after receiving one dose of GBS Trivalent Vaccine.Threshold values of 0.1, 0.2, 0.5, 1, 2, 3, 5, and 8 μg/mL were used for serum concentrations for maternal subjects.</description>
          <population>FAS (Maternal Subjects)</population>
          <units>Percentage of maternal subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 0.2 µg/mL(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5 µg/mL(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 µg/mL(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 µg/mL(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3 µg/mL(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5 µg/mL(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 8 µg/mL(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.1 µg/mL(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.2 µg/mL(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5 µg/mL(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 µg/mL(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 µg/mL(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3 µg/mL(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5 µg/mL(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 8 µg/mL(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.1 µg/mL(Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.2 µg/mL(Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5 µg/mL(Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 µg/mL(Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 µg/mL(Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3 µg/mL(Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5 µg/mL(Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 8 µg/mL(Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Solicited Local Adverse Events (AEs)</title>
        <description>Safety was assessed in terms of the number of subjects with solicited local AEs after receiving one dose of the GBS Trivalent Vaccine</description>
        <time_frame>From 6 Hours to Day 7 After Each Vaccination, for up to 24 weeks</time_frame>
        <population>Safety Set (Solicited AEs, Maternal Subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>HIVposCD4LOW_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O2">
            <title>HIVposCD4HIGH_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O3">
            <title>HIVneg_Maternal</title>
            <description>HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Solicited Local Adverse Events (AEs)</title>
          <description>Safety was assessed in terms of the number of subjects with solicited local AEs after receiving one dose of the GBS Trivalent Vaccine</description>
          <population>Safety Set (Solicited AEs, Maternal Subjects)</population>
          <units>percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis(87, 88, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema(87, 88, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration(87, 88, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling(87, 88, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain(87, 88, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Solicited Systemic AEs</title>
        <description>Safety was assessed in terms of the number of subjects with solicited systemic AEs after receiving one dose of the GBS Trivalent Vaccine</description>
        <time_frame>From 6 Hours to Day 7 After Each Vaccination, for up to 24 weeks</time_frame>
        <population>Safety Set (Solicited AEs, Maternal Subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>HIVposCD4LOW_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O2">
            <title>HIVposCD4HIGH_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O3">
            <title>HIVneg_Maternal</title>
            <description>HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Solicited Systemic AEs</title>
          <description>Safety was assessed in terms of the number of subjects with solicited systemic AEs after receiving one dose of the GBS Trivalent Vaccine</description>
          <population>Safety Set (Solicited AEs, Maternal Subjects)</population>
          <units>percentages of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chills(87,88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea(87,88,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise(87,88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia(87,88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia(87,88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache(87,88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue(87,88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash(87,88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( ≥ 38°C)(87, 88, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature(&lt;38°C)(87, 88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature(38-38.4°C)(87, 88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature(38.5-38.9°C)(87, 88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature(39-39.4°C)(87, 88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature(39.5-39.9°C)(87, 88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature(≥ 40°C)(87, 88,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic antipyr. meds(Other indicators)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home(Other indicators)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Who Experienced Unsolicited Adverse Events</title>
        <description>Safety was assessed in terms of the number of subjects who experienced Unsolicited Adverse Events after receiving one dose of the GBS Trivalent Vaccine</description>
        <time_frame>Day 1 to Study Termination, for up to 24 weeks</time_frame>
        <population>Safety Set (Unsolicited AEs, Maternal Subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>HIVposCD4LOW_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O2">
            <title>HIVposCD4HIGH_Maternal</title>
            <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
          <group group_id="O3">
            <title>HIVneg_Maternal</title>
            <description>HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Who Experienced Unsolicited Adverse Events</title>
          <description>Safety was assessed in terms of the number of subjects who experienced Unsolicited Adverse Events after receiving one dose of the GBS Trivalent Vaccine</description>
          <population>Safety Set (Unsolicited AEs, Maternal Subjects)</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to withdrawal from study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Infants Who Experienced Unsolicited Adverse Events</title>
        <description>Safety in Infants was assessed in terms of the number of subjects who experienced Unsolicited Adverse Events since birth to study termination</description>
        <time_frame>Birth to Study Termination, for up to 24 weeks</time_frame>
        <population>Safety Set (Unsolicited AEs, Infants)</population>
        <group_list>
          <group group_id="O1">
            <title>HIVposCD4LOW (Infants)</title>
            <description>Infants born to HIV-antibody positive maternal subjects with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL</description>
          </group>
          <group group_id="O2">
            <title>HIVposCD4HIGH (Infants)</title>
            <description>Infants born to HIV-antibody positive maternal subjects with CD4+ count &gt;350 cells/µL</description>
          </group>
          <group group_id="O3">
            <title>HIVneg (Infants)</title>
            <description>Infants born to HIV-antibody negative maternal subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Infants Who Experienced Unsolicited Adverse Events</title>
          <description>Safety in Infants was assessed in terms of the number of subjects who experienced Unsolicited Adverse Events since birth to study termination</description>
          <population>Safety Set (Unsolicited AEs, Infants)</population>
          <units>percentages of Infant subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to withdrawal from study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Transfer Ratio Between Infant Antibody Level (μg/mL) and Maternal Antibody Level (μg/mL), for GBS Serotypes Ia, Ib and III at Delivery/Birth.</title>
        <description>The Geometric mean transfer ratio of GBS-specific Ab against serotypes Ia, Ib and III at delivery is calculated as the geometric mean of the pairwise ratios between the antibody concentrations from infant at birth and to maternal serum concentration at delivery.</description>
        <time_frame>Day of delivery/birth</time_frame>
        <population>Full Analysis Set (FAS)-Maternal and Infant Subjects: Maternal subjects provided at least one evaluable serum sample result at delivery; infant subjects provided at least one evaluable sample result at birth (from cord blood, or peripheral blood within 72 hours when cord blood was unavailable).</population>
        <group_list>
          <group group_id="O1">
            <title>HIVposCD4LOW</title>
            <description>Maternal Subjects:HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine Infants:Infants born to HIV-antibody positive maternal subjects with CD4+ count ≤350 cells/µL but &gt; 50 cells/µL</description>
          </group>
          <group group_id="O2">
            <title>HIVposCD4HIGH</title>
            <description>Maternal Subjects:HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/µL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine Infants:Infants born to HIV-antibody positive maternal subjects with CD4+ count &gt;350 cells/µL</description>
          </group>
          <group group_id="O3">
            <title>HIVneg</title>
            <description>Maternal subjects: HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent Vaccine.
Infants: Infants born to HIV-antibody negative maternal subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Transfer Ratio Between Infant Antibody Level (μg/mL) and Maternal Antibody Level (μg/mL), for GBS Serotypes Ia, Ib and III at Delivery/Birth.</title>
          <description>The Geometric mean transfer ratio of GBS-specific Ab against serotypes Ia, Ib and III at delivery is calculated as the geometric mean of the pairwise ratios between the antibody concentrations from infant at birth and to maternal serum concentration at delivery.</description>
          <population>Full Analysis Set (FAS)-Maternal and Infant Subjects: Maternal subjects provided at least one evaluable serum sample result at delivery; infant subjects provided at least one evaluable sample result at birth (from cord blood, or peripheral blood within 72 hours when cord blood was unavailable).</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.49" upper_limit="0.69"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.51" upper_limit="0.72"/>
                    <measurement group_id="O3" value="0.72" lower_limit="0.61" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib (41,54,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" lower_limit="0.38" upper_limit="0.69"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.5" upper_limit="0.83"/>
                    <measurement group_id="O3" value="0.49" lower_limit="0.38" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III (53,44,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.44" upper_limit="0.82"/>
                    <measurement group_id="O2" value="0.51" lower_limit="0.36" upper_limit="0.72"/>
                    <measurement group_id="O3" value="0.56" lower_limit="0.43" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group Ratios (Serotype Ia)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>98.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group ratios (Serotype Ia)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>98.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group ratios (Serotype Ia)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>98.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group ratios (Serotype Ib)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>98.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group ratios (Serotype Ib)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>98.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group ratios (Serotype Ib)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>98.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group ratios (Serotype III)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>98.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group ratios (Serotype III)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>98.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group ratios (Serotype III)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>98.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period, for up to 24 weeks</time_frame>
      <desc>All AEs or SAEs occurring from previous visit, relevant medical history, any new or continuing concomitant medications were recorded at the next visit. All AEs were collected until day 31 following vaccination and all AEs requiring a physician’s visit from day 31 until the end of study. All SAEs were monitored throughout the entire study period.</desc>
      <group_list>
        <group group_id="E1">
          <title>HIVposCD4LOW (Infants)</title>
          <description>Infants born to HIV-antibody positive maternal subjects with CD4+ count ≤350 cells/μL but &gt; 50 cells/μL</description>
        </group>
        <group group_id="E2">
          <title>HIVposCD4HIGH (Infants)</title>
          <description>Infants born to HIV-antibody positive maternal subjects with CD4+ count &gt;350 cells/μL .</description>
        </group>
        <group group_id="E3">
          <title>HIVneg (Infants)</title>
          <description>Infants born to HIV-antibody negative maternal subjects</description>
        </group>
        <group group_id="E4">
          <title>Total (Infants)</title>
          <description>Total number of Infants participated in the study</description>
        </group>
        <group group_id="E5">
          <title>HIVposCD4LOW_Maternal Subjects</title>
          <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/μL but &gt; 50 cells/μL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent vaccine.</description>
        </group>
        <group group_id="E6">
          <title>HIVposCD4HIGH_Maternal Subjects</title>
          <description>HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count &gt;350 cells/μL received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent vaccine.</description>
        </group>
        <group group_id="E7">
          <title>HIVneg_Maternal Subjects</title>
          <description>HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of 5 μg of each of the 3 glycoconjugates present in the GBS Trivalent vaccine.</description>
        </group>
        <group group_id="E8">
          <title>Total Maternal Subjects</title>
          <description>Total number of Maternal subjects participated in the study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="82" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC DISEASE OF NEWBORN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>CARDIAC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>CHROMOSOMAL DELETION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>CONGENITAL PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PATENT DUCTUS ARTERIOSUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>TALIPES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>TRISOMY 21</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEELING JITTERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AMNIOTIC CAVITY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>BREAST ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>ENDOMETRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>MALARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>MENINGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>SEPSIS NEONATAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>SYPHILIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PERINEAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>UTERINE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>HYPERNATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>HYPOXIC-ISCHAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>BREECH PRESENTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>CAPUT SUCCEDANEUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>CEPHALO-PELVIC DISPROPORTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>CERVIX DYSTOCIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>ECLAMPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>FAILED INDUCTION OF LABOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>FALSE LABOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>FOETAL DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>GESTATIONAL DIABETES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>GESTATIONAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE IN PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>HYPEREMESIS GRAVIDARUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>JAUNDICE NEONATAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>LOW BIRTH WEIGHT BABY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>POSTPARTUM HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PRE-ECLAMPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PREMATURE BABY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PREMATURE DELIVERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PREMATURE LABOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PRETERM PREMATURE RUPTURE OF MEMBRANES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PROLONGED LABOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PROLONGED PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PROLONGED RUPTURE OF MEMBRANES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>RETAINED PLACENTA OR MEMBRANES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>RETAINED PRODUCTS OF CONCEPTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>STILLBIRTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>THREATENED LABOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>TRANSVERSE PRESENTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>UTERINE CERVIX STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>NEONATAL ASPHYXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>NEONATAL ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>NEONATAL RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>TRANSIENT TACHYPNOEA OF THE NEWBORN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MELANOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PETECHIAE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CAESAREAN SECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>SHOCK HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>SUBGALEAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="68" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="71" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="194" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="50" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="40" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="42" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="90" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="79" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="48" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PERINEAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="62" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="57" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="43" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="41" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="96" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

